Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.74 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.74 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.58 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.51 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9001558 | 0.86 | ESR1 (0.60) | ESR1ESR2TLR7MAPTCHRNB4 | |
| SCHEMBL12464719 | 0.85 | TLR7 (0.64) | ESR1ESR2TLR7TLR9NPC1 | |
| SCHEMBL4228077 | 0.82 | ESR1 (0.74) | ESR1ESR2NPC1RAB9AMAPT | |
| SCHEMBL18726463 | 0.82 | NPC1 (0.61) | ESR1ESR2TLR7TLR9NPC1 | |
| SCHEMBL27090228 | 0.82 | ESR1 (0.96) | ESR1ESR2NPC1RAB9AMAPT | |
| SCHEMBL12464721 | 0.81 | TLR7 (0.85) | ESR1ESR2TLR7TLR9MAPT | |
| SCHEMBL12396814 | 0.81 | ESR1 (0.63) | ESR1ESR2NPC1RAB9AMAPT | |
| SCHEMBL12397065 | 0.81 | TLR7 (0.79) | ESR1ESR2TLR7TLR9NPC1 | |
| SCHEMBL2158317 | 0.80 | ESR1 (1.00) | ESR1ESR2NPC1RAB9AMAPT | |
| SCHEMBL18726400 | 0.80 | TLR7 (0.58) | ESR1ESR2TLR7TLR9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350032-B1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | EISAI R&D MAN CO LTD (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-8354400-B2 | Benzoxazole compounds and methods of use | EISAI R&D CO., LTD. (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20110183967-A1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-28 | — | — | US | disclosed |
| WO-2010036905-A1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036908-A1 | USE OF BENZOXAZOLE COMPOUNDS IN THE TREATMENT OF MALARIA | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183967-A1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | CYP4X1, CYP3A5, CYP3A7 | ESR1 2407/4885ESR2 2935/4885TLR7 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.